Program
STR-P004
Also written as “STR-P004 dose group”.
Its studies are mostly in Autoimmune Diseases · Lymphoma, Non-Hodgkin, led by Starna Therapeutics.
Furthest: early phase 1, since May 19, 20253 company-led studies, 3 open or runningNext primary completion: Feb 1, 2027
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Starna Therapeutics | 33 open or running | early phase 1since May 19, 2025 | May 19, 2025 | Feb 1, 2027NCT07363954 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 19, 2025First study: early phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT07003178 · 30 planned · China
- Nov 17, 2025No phase study in Acute Lymphobkastic LeukemiaNCT07245251 · 11 planned
- Jan 15, 2026No phase study in Autoimmune DiseasesNCT07363954 · 9 planned
Ahead
- Nov 2, 2026Primary completion: no phase study in Acute Lymphobkastic LeukemiaNCT07245251
- Feb 1, 2027Primary completion: no phase study in Autoimmune DiseasesNCT07363954
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07363954Autoimmune Diseases | – | Not yet recruiting | Feb 1, 2027 | 9 |
| NCT07245251Acute Lymphobkastic Leukemia | – | Not yet recruiting | Nov 2, 2026 | 11 |
| NCT07003178Lymphoma, Non-Hodgkin · China | Early 1 | Not yet recruiting | Apr 2026 | 30 |
How it is read
Names in the registry
- “STR-P004”, 2 entries
- “STR-P004 dose group”, 1 entry
Conditions, from the studies’ own filings
- Autoimmune Diseases, 1 study
- Lymphoma, Non-Hodgkin, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.